

The inhibitory powers ...

... of a next-generation inhibitor were carefully balanced so that it is equally potent on the RET kinase and $VEGFR_2$. In their Communication on page 8717 ff., H.-y. Li, M. Santoro, et al. report the optimization of a dual inhibitor for the treatment of RET-driven malignancies through synergistic medicinal chemistry. The inhibitor is capable of simultaneously treating the parenchyma (RET) and stroma (VEGFR₂) at the same therapeutic dose.

WILEY-VCH